Program
CK-586
Also written as “CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)” and “CK-4021586”.
Its studies are mostly in Heart Failure, led by Cytokinetics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cytokinetics | 21 open or running | phase 2since Jan 21, 2025 | May 17, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT05877053 · 102 enrolled · United States
- Jan 21, 2025Phase 2 study in Heart FailureNCT06793371 · 60 planned · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06793371Heart Failure · United States | 2 | Recruiting | Sep 2026 | 60 |
| NCT05877053Healthy Participants · United States | 1 | Completed | Nov 20, 2024 | 102 |
How it is read
Names in the registry
- “CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)”, 1 entry
- “CK-4021586”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.